At CRT 2024, Dr Thomas Waggoner presented 30-day data from the DurAVR® transcatheter heart valve (THV) Early Feasibility Study (EFS). The data substantiates the promising hemodynamic (blood flow) results reported to date with the DurAVR® THV, a new class of biomimetic THV designed to restore normal blood flow in aortic stenosis. The latest data includes 30-day results for all 28 patients treated in the First-In-Human Study (Cohorts 1-4) in addition to 30-day results for all 15 patients treated in the US Early Feasibility Study. View the full presentation below.